Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

First Posted Date: 2012-01-19

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 355

Registration Number: NCT01512420

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4917838

First Posted Date: 2012-01-18

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT01510899

An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Completed

Conditions: Hepatitis C, Chronic

First Posted Date: 2012-01-11

Last Posted Date: 2017-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 672

Registration Number: NCT01508130

Locations: 🇺🇸
Florida Center for Gastroenterology, Largo, Florida, United States
🇺🇸
HMRI Liver Center, Pasadena, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 63 locations

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Placebo
Drug: GC33

First Posted Date: 2012-01-10

Last Posted Date: 2020-04-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 185

Registration Number: NCT01507168

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇫🇷
Hôpital Saint Antoine; Service Hépathologie, Paris, France

and more 54 locations

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Capecitabine/Oxaliplatin
Drug: Fluorouracil/Folinic Acid/Oxaliplatin
Drug: Fluorouracil/Folinic Acid/Irinotecan
Drug: Fluorouracil +/- Folinic Acid
Drug: Capecitabine

First Posted Date: 2012-01-09

Last Posted Date: 2018-05-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 719

Registration Number: NCT01506167

Locations: 🇬🇧
Walsall Manor Hospital, Walsall, United Kingdom
🇬🇧
University Hospital of North Staffordhire, Blackpool, United Kingdom
🇬🇧
Royal United Hospital Bath; Diabetes and Lipid Research, Wolfson Centre, Bath, United Kingdom

and more 39 locations

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: RO5509554
Drug: Paclitaxel

First Posted Date: 2011-12-19

Last Posted Date: 2018-03-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 217

Registration Number: NCT01494688

Locations: 🇫🇷
Centre Leon Berard; Departement Oncologie Medicale, Lyon, France
🇺🇸
Univ of Pennsylvania Med Ctr, Philadelphia, Pennsylvania, United States
🇫🇷
Institut Curie; Oncologie Medicale, Paris, France

and more 4 locations

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: RO4917838
Drug: valproate

First Posted Date: 2011-12-19

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT01495104

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

Phase 2

Completed

Conditions: Hypertension, Glaucoma, Open-Angle

Interventions: Drug: Placebo
Drug: RO5093151

First Posted Date: 2011-12-15

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 31

Registration Number: NCT01493271

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Phase 1

Completed

Conditions: Breast Cancer, Colorectal Cancer

Interventions: Drug: capecitabine RTD
Drug: capecitabine [Xeloda]

First Posted Date: 2011-12-15

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 37

Registration Number: NCT01493336

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab
Drug: Aromatase Inhibitor
Drug: Trastuzumab
Drug: Induction Chemotherapy

First Posted Date: 2011-12-14

Last Posted Date: 2020-10-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 258

Registration Number: NCT01491737

Locations: 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇺🇸
Washington University School of Medicine; Internal Medicine - Renal, Saint Louis, Missouri, United States
🇺🇸
Ironwood Cancer TX & Rsch Ctrs, Chandler, Arizona, United States

and more 79 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy